Who Buys Doxorubicin from India — 899 Importers Behind a $67.3M Market
India's doxorubicin import market is served by 899 active buyers who collectively imported $67.3M across 3,492 shipments. TARO PHARMACEUTICALS INC. (CANADA) leads with a 11.5% market share, followed by DR REDDYS LABORATORIES,INC and SUN PHARMACEUTICAL INDUSTRIES,INC.. The top 5 buyers together control 35.0% of total import value, reflecting a moderately competitive buyer landscape.
Top Doxorubicin Importers — Ranked by Import Value
TARO PHARMACEUTICALS INC. (CANADA) is the leading doxorubicin importer from India, holding a 11.5% share of the $67.3M market across 3,492 shipments from 899 buyers. The top 5 buyers — TARO PHARMACEUTICALS INC. (CANADA), DR REDDYS LABORATORIES,INC (UNITED STATES), SUN PHARMACEUTICAL INDUSTRIES,INC. (UNITED STATES), SUN PHARMACEUTICAL INDUSTRIES INC (UNITED STATES), TARO PHARMACEUTICALS INC (CANADA) — collectively control 35.0% of total import value.
Top Doxorubicin Buyers & Importers
Ranked by import value · 899 active buyers · Indian Customs (DGFT) data
| # | Buyer & Formulations | Value | Suppliers | Share |
|---|---|---|---|---|
| 1 | TARO PHARMACEUTICALS INC.CANADA TARO-DOXORUBICIN HYDROCHLORIDE LIPOSOME | $7.7M | 5 | 11.5% |
| 2 | DR REDDYS LABORATORIES,INCUNITED STATES DOXORUBICIN HYDROCHLORIDE LIPOSOME INJEC | $7.0M | 5 | 10.3% |
| 3 | SUN PHARMACEUTICAL INDUSTRIES,INC.UNITED STATES DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECLIPOSOMAL DOXORUBICIN SUN 20 MG/10 ML , 10ML)LIPOSOMAL DOXORUBICIN SUN 20 MG/10 ML PA | $3.7M | 5 | 5.5% |
| 4 | SUN PHARMACEUTICAL INDUSTRIES INCUNITED STATES DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECLIPOSOMAL DOXORUBICIN SUN 20 MG/10 ML , 10ML)LIPOSOMAL DOXORUBICIN SUN 20 MG/10 ML PA | $2.7M | 5 | 4.0% |
| 5 | TARO PHARMACEUTICALS INCCANADA TARO-DOXORUBICIN HYDROCHLORIDE LIPOSOME | $2.4M | 5 | 3.6% |
| 6 | TARO PHARMACEUTICAL INC.CANADA TARO-DOXORUBICIN HYDROCHLORIDE LIPOSOME | $2.4M | 5 | 3.5% |
| 7 | RXCROSSROADS 3PL LLCUNITED STATES DOXORUBICIN HYDROCHLORIDE LIPOSOME INJEC | $2.2M | 5 | 3.2% |
| 8 | SUN PHARMACEUTICAL INDUSTRIES INC.,UNITED STATES DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECLIPOSOMAL DOXORUBICIN SUN 20 MG/10 ML , 10ML)LIPOSOMAL DOXORUBICIN SUN 20 MG/10 ML PA | $2.0M | 5 | 3.0% |
| 9 | DR REDDYS LABORATORIES INCUNITED STATES DOXORUBICIN HYDROCHLORIDE LIPOSOME INJEC | $1.5M | 5 | 2.3% |
| 10 | SUN PHARMA ANZ PTY LTDAUSTRALIA DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECLIPOSOMAL DOXORUBICIN SUN 20 MG/10 ML , 10ML)LIPOSOMAL DOXORUBICIN SUN 20 MG/10 ML PA | $1.2M | 5 | 1.8% |
| 11 | NORTHSTAR RX LLCUNITED STATES DOXORUBICIN HYDROCHLORIDE LIPOSOME INJEC | $1.2M | 5 | 1.8% |
| 12 | HAPHARCO J S C BRANCHVIETNAM CHEMODOX 2MG/ML, 10ML INJECTION [PACK: 1 VIAL]CHEMODOX 2MG/ML, 10ML INJECTION [PACK: 1 VIAL]VLS | $998.5K | 5 | 1.5% |
| 13 | HAPHARCOJ S CBRANCHVIETNAM CHEMODOX 2MG/ML, 10ML INJECTION [PACK: 1 VIAL]CHEMODOX 2MG/ML, 10ML INJECTION [PACK: 1 VIAL]VLS | $995.8K | 5 | 1.5% |
| 14 | HAPHARCO J.S.C BRANCHVIETNAM CHEMODOX 2MG/ML, 10ML INJECTION [PACK: 1 VIAL]CHEMODOX 2MG/ML, 10ML INJECTION [PACK: 1 VIAL]VLS | $952.0K | 5 | 1.4% |
| 15 | SUN PHARMACEUTICAL INDUSTRIES, INC.UNITED STATES DOXORUBICIN HYDROCHLORIDE LIPOSOME INJECLIPOSOMAL DOXORUBICIN SUN 20 MG/10 ML , 10ML)LIPOSOMAL DOXORUBICIN SUN 20 MG/10 ML PA | $902.0K | 5 | 1.3% |
Related Analysis
Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Which companies are buying Doxorubicin — and from which countries?
Flow of Doxorubicin exports from India: each country's share and the named importers behind the numbers
Doxorubicin — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Market Analysis: Top Importing Countries & Their Importers
1United States
United States emerges as the first largest importing country, achieving a total trade value of $26.5M through 102 shipments. This represents a market share of 39.4% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• DR REDDYS LABORATORIES,INC - $7.0M (26.3% of country's total business)
• SUN PHARMACEUTICAL INDUSTRIES,INC. - $3.7M (14.0% of country's total business)
• SUN PHARMACEUTICAL INDUSTRIES INC - $2.7M (10.2% of country's total business)
• RXCROSSROADS 3PL LLC - $2.2M (8.2% of country's total business)
• SUN PHARMACEUTICAL INDUSTRIES INC., - $2.0M (7.5% of country's total business)
• Rest of United States's importers - $9.0M (33.8% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $259.9K, indicating premium pricing strategy compared to the market average of $19.3K.
United States is a key market for Doxorubicin imports, representing 39.4% of total trade value.
2Canada
Canada emerges as the second largest importing country, achieving a total trade value of $12.7M through 15 shipments. This represents a market share of 18.9% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Canada has a diverse importer base, with their top importers including:
• TARO PHARMACEUTICALS INC. - $7.7M (60.7% of country's total business)
• TARO PHARMACEUTICALS INC - $2.4M (19.0% of country's total business)
• TARO PHARMACEUTICAL INC. - $2.4M (18.6% of country's total business)
Key Insight: Canada demonstrates strong market positioning with an average shipment value of $848.7K, indicating premium pricing strategy compared to the market average of $19.3K.
Canada is a key market for Doxorubicin imports, representing 18.9% of total trade value.
3Mozambique
Mozambique emerges as the third largest importing country, achieving a total trade value of $3.1M through 7 shipments. This represents a market share of 4.7% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Mozambique has a diverse importer base, with their top importers including:
• MINISTERIO DA SAUDE/ - $899.5K (28.7% of country's total business)
• MINISTRIO DA SADE/ - $808.0K (25.8% of country's total business)
Key Insight: Mozambique demonstrates strong market positioning with an average shipment value of $448.2K, indicating premium pricing strategy compared to the market average of $19.3K.
Mozambique is a key market for Doxorubicin imports, representing 4.7% of total trade value.
4Vietnam
Vietnam emerges as the fourth largest importing country, achieving a total trade value of $2.9M through 9 shipments. This represents a market share of 4.4% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Vietnam has a diverse importer base, with their top importers including:
• HAPHARCO J S C BRANCH - $998.5K (33.9% of country's total business)
• HAPHARCOJ S CBRANCH - $995.8K (33.8% of country's total business)
• HAPHARCO J.S.C BRANCH - $952.0K (32.3% of country's total business)
Key Insight: Vietnam demonstrates strong market positioning with an average shipment value of $327.5K, indicating premium pricing strategy compared to the market average of $19.3K.
Vietnam is a key market for Doxorubicin imports, representing 4.4% of total trade value.
5Saudi Arabia
Saudi Arabia emerges as the fifth largest importing country, achieving a total trade value of $2.2M through 0 shipments. This represents a market share of 3.2% of the total market activity, demonstrating their significant presence in the industry.
Key Insight: Saudi Arabia demonstrates strong market positioning with an average shipment value of $2.2M, indicating premium pricing strategy compared to the market average of $19.3K.
Saudi Arabia is a key market for Doxorubicin imports, representing 3.2% of total trade value.
Buyer Segment Analysis
TransData Nexus Doxorubicin buyer market intelligence
1Buyer Segment Analysis
The buyer landscape for Doxorubicin imported from India encompasses several key segments:
1. Pharmaceutical Companies: Entities like TARO PHARMACEUTICALS INC. (Canada) and DR. REDDY'S LABORATORIES, INC. (United States) are prominent buyers. These companies procure Doxorubicin to manufacture and distribute under their brand names, ensuring a consistent supply to meet market demand. Their purchasing patterns typically involve large, regular orders to maintain inventory levels and fulfill contractual obligations.
2. Distributors: Organizations such as RXCROSSROADS 3PL LLC (United States) function as intermediaries, purchasing Doxorubicin in bulk and supplying it to healthcare providers, pharmacies, and hospitals. Distributors often place substantial orders to leverage economies of scale and ensure product availability across various regions.
3. Contract Manufacturers: Companies like SUN PHARMACEUTICAL INDUSTRIES, INC. (United States) and SUN PHARMA ANZ PTY LTD (Australia) may also act as contract manufacturers, producing Doxorubicin formulations for other pharmaceutical firms. Their procurement is driven by production schedules and client demands, leading to variable order sizes and frequencies.
Country-Specific Import Regulations
TransData Nexus Doxorubicin buyer market intelligence
1Country-Specific Import Regulations
United States
1. Regulatory Authority: U.S. Food and Drug Administration (FDA).
2. Import Registration Process: Importers must ensure that Doxorubicin is FDA-approved. This involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) for generic versions.
3. Estimated Timeline for Registration: The FDA review process typically takes 10 months for standard applications, though priority reviews can be expedited to 6 months.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products under this HS code are generally duty-free in the United States.
Canada
1. Regulatory Authority: Health Canada.
2. Import Registration Process: Importers must obtain a Drug Identification Number (DIN) by submitting a New Drug Submission (NDS) or an Abbreviated New Drug Submission (ANDS) for generics.
3. Estimated Timeline for Registration: The review process can take up to 300 days for standard submissions.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products under this HS code are typically duty-free in Canada.
Mozambique
1. Regulatory Authority: Pharmacy Department of the Ministry of Health.
2. Import Registration Process: Importers must register pharmaceutical products by submitting a dossier that includes quality, safety, and efficacy data.
3. Estimated Timeline for Registration: The registration process can take approximately 12 months.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products may be subject to import duties; specific rates should be confirmed with local customs authorities.
Vietnam
1. Regulatory Authority: Drug Administration of Vietnam (DAV).
2. Import Registration Process: Importers must obtain a Marketing Authorization by submitting a registration dossier, including clinical data and manufacturing information.
3. Estimated Timeline for Registration: The process typically takes 12 to 24 months.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products are generally subject to a 5% import duty.
Saudi Arabia
1. Regulatory Authority: Saudi Food and Drug Authority (SFDA).
2. Import Registration Process: Importers must register pharmaceutical products by submitting a Common Technical Document (CTD) that includes quality, safety, and efficacy data.
3. Estimated Timeline for Registration: The registration process can take 12 to 18 months.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products are typically exempt from import duties in Saudi Arabia.
Demand Drivers & Market Opportunity
TransData Nexus Doxorubicin buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Doxorubicin in importing countries is primarily driven by the prevalence of cancers such as breast cancer, leukemia, and lymphomas, for which Doxorubicin is a standard chemotherapy agent. According to the World Health Organization (WHO), cancer remains a leading cause of morbidity and mortality worldwide, necessitating effective treatment options.
Government healthcare programs and the expansion of universal health coverage have also significantly influenced demand. Many countries have included Doxorubicin in their national essential medicines lists, aligning with the WHO Essential Medicines List, which recommends Doxorubicin for various cancers. Tender-based purchasing is common, especially in low- and middle-income countries, to procure medicines cost-effectively. The WHO suggests that countries use tendering for pharmaceutical products, considering factors such as product quality, availability, and supply security.
With 899 buyers across 136 countries, the global reach of Doxorubicin underscores its critical role in cancer treatment protocols and the ongoing efforts to make essential medicines accessible worldwide.
Common Questions — Doxorubicin Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest doxorubicin buyer importing from India?
Based on import volume and value, TARO PHARMACEUTICALS INC. (CANADA) leads with $7.7M in imports and a 11.5% market share — the highest of any single doxorubicin importer. DR REDDYS LABORATORIES,INC (UNITED STATES) and SUN PHARMACEUTICAL INDUSTRIES,INC. (UNITED STATES) are the next largest buyers.
QHow many companies buy doxorubicin from India?
There are 899 active doxorubicin buyers importing from India, with a combined market of $67.3M across 3,492 shipments to 136 countries. The top 5 buyers hold 35.0% of total import value, while the remaining 894 buyers handle the other 65.0%.
QWhich countries import the most doxorubicin from India?
The top importing countries for doxorubicin from India are United States (39.4%), Canada (18.9%), Mozambique (4.7%), Vietnam (4.4%), Saudi Arabia (3.2%). These markets represent the largest demand centres for Indian pharmaceutical exports of doxorubicin, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for doxorubicin from India?
The average import transaction value for doxorubicin from India is $19.3K, with an average unit price of $18.29 per unit. Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
Buyer Segment Analysis
TransData Nexus Doxorubicin buyer market intelligence
1Buyer Segment Analysis
The buyer landscape for Doxorubicin imported from India encompasses several key segments:
1. Pharmaceutical Companies: Entities like TARO PHARMACEUTICALS INC. (Canada) and DR. REDDY'S LABORATORIES, INC. (United States) are prominent buyers. These companies procure Doxorubicin to manufacture and distribute under their brand names, ensuring a consistent supply to meet market demand. Their purchasing patterns typically involve large, regular orders to maintain inventory levels and fulfill contractual obligations.
2. Distributors: Organizations such as RXCROSSROADS 3PL LLC (United States) function as intermediaries, purchasing Doxorubicin in bulk and supplying it to healthcare providers, pharmacies, and hospitals. Distributors often place substantial orders to leverage economies of scale and ensure product availability across various regions.
3. Contract Manufacturers: Companies like SUN PHARMACEUTICAL INDUSTRIES, INC. (United States) and SUN PHARMA ANZ PTY LTD (Australia) may also act as contract manufacturers, producing Doxorubicin formulations for other pharmaceutical firms. Their procurement is driven by production schedules and client demands, leading to variable order sizes and frequencies.
Country-Specific Import Regulations
TransData Nexus Doxorubicin buyer market intelligence
1Country-Specific Import Regulations
United States
1. Regulatory Authority: U.S. Food and Drug Administration (FDA).
2. Import Registration Process: Importers must ensure that Doxorubicin is FDA-approved. This involves submitting a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) for generic versions.
3. Estimated Timeline for Registration: The FDA review process typically takes 10 months for standard applications, though priority reviews can be expedited to 6 months.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products under this HS code are generally duty-free in the United States.
Canada
1. Regulatory Authority: Health Canada.
2. Import Registration Process: Importers must obtain a Drug Identification Number (DIN) by submitting a New Drug Submission (NDS) or an Abbreviated New Drug Submission (ANDS) for generics.
3. Estimated Timeline for Registration: The review process can take up to 300 days for standard submissions.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products under this HS code are typically duty-free in Canada.
Mozambique
1. Regulatory Authority: Pharmacy Department of the Ministry of Health.
2. Import Registration Process: Importers must register pharmaceutical products by submitting a dossier that includes quality, safety, and efficacy data.
3. Estimated Timeline for Registration: The registration process can take approximately 12 months.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products may be subject to import duties; specific rates should be confirmed with local customs authorities.
Vietnam
1. Regulatory Authority: Drug Administration of Vietnam (DAV).
2. Import Registration Process: Importers must obtain a Marketing Authorization by submitting a registration dossier, including clinical data and manufacturing information.
3. Estimated Timeline for Registration: The process typically takes 12 to 24 months.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products are generally subject to a 5% import duty.
Saudi Arabia
1. Regulatory Authority: Saudi Food and Drug Authority (SFDA).
2. Import Registration Process: Importers must register pharmaceutical products by submitting a Common Technical Document (CTD) that includes quality, safety, and efficacy data.
3. Estimated Timeline for Registration: The registration process can take 12 to 18 months.
4. Import Tariff/Duty for HS 30049046: Pharmaceutical products are typically exempt from import duties in Saudi Arabia.
Demand Drivers & Market Opportunity
TransData Nexus Doxorubicin buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Doxorubicin in importing countries is primarily driven by the prevalence of cancers such as breast cancer, leukemia, and lymphomas, for which Doxorubicin is a standard chemotherapy agent. According to the World Health Organization (WHO), cancer remains a leading cause of morbidity and mortality worldwide, necessitating effective treatment options.
Government healthcare programs and the expansion of universal health coverage have also significantly influenced demand. Many countries have included Doxorubicin in their national essential medicines lists, aligning with the WHO Essential Medicines List, which recommends Doxorubicin for various cancers. Tender-based purchasing is common, especially in low- and middle-income countries, to procure medicines cost-effectively. The WHO suggests that countries use tendering for pharmaceutical products, considering factors such as product quality, availability, and supply security.
With 899 buyers across 136 countries, the global reach of Doxorubicin underscores its critical role in cancer treatment protocols and the ongoing efforts to make essential medicines accessible worldwide.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Buyer Identification: 899 global importers of Doxorubicin identified from consignee fields in DGFT shipping bill records.
- 2.Import Value Analysis: Total import value aggregated from 3,492 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Geographic Distribution: Buyer imports distributed across 136 destination countries with market share per buyer calculated from capped values.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,492 Verified Shipments
899 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists